Weight Loss Injection Launched in India: Obesity continues to surge across India due to poor diet, sedentary lifestyles, and lack of exercise. Danish pharmaceutical giant Novo Nordisk has launched its highly anticipated weight loss injection ‘Wegovy’ in India. This once-weekly injectable medication has received global acclaim for its efficacy in weight management.
Follow the Latest Updates Group:
https://whatsapp.com/channel/0029Vb2Z6498F2pHMwM9YA1S
According to Vikrant Shrotriya, Managing Director of Novo Nordisk India, Wegovy is currently being distributed and is expected to be available in pharmacies by the end of June 2025.
Wegovy has been approved for chronic weight management and is meant for individuals who are obese or overweight with related health issues such as type-2 diabetes, hypertension, or cardiovascular disease. Unlike traditional methods requiring strict diet and exercise, this medication provides a pharmacological solution, although it should still be used under medical supervision.
Dosage and Pricing Details –
Wegovy will be available in the following dosage variants:
0.25 mg, 0.5 mg, 1 mg: ₹4,366 per pen
Monthly treatment cost: ₹17,345
1.7 mg: ₹24,280/month
2.4 mg (highest dosage): ₹26,015/month
The injection is administered once a week, and dosage is typically escalated over time as per medical guidance.
Background and Impact:
With obesity being a major contributor to chronic illnesses such as diabetes, heart disease, and high blood pressure, Wegovy’s India launch could be a game-changer. The drug has already made headlines globally for its effectiveness, particularly in the United States and Europe, where it has been widely prescribed and praised.
Experts caution that while Wegovy may reduce the burden of lifestyle modification, doctor consultation is mandatory before use. It’s not a substitute for healthy living but a supplement for those with severe weight-related health risks.
